FRISSORA MARK P 4

What Happened
Mark P. Frissora, a director of BioAdaptives, acquired 4,386 shares of Series D Convertible Preferred Stock on April 1, 2026. The Form 4 reports the transaction as an "other acquisition" (code J) with a reported price of $0.00 — these preferred shares were issued as compensation for board services rather than an open‑market purchase. The securities are convertible into common stock at a ratio of 1 preferred → 100 common, subject to limits described below.

Key Details

• Transaction date: 2026-04-01; filing date: 2026-04-03 (appears timely — filed within two business days).
• Shares acquired: 4,386 shares of Series D Convertible Preferred Stock; reported price $0.00 (compensation).
• Conversion: each preferred converts into 100 shares of common stock (i.e., potentially 438,600 common shares in total), subject to a 4.9% beneficial ownership limitation and a six‑month conversion hold after issuance (conversion permitted earlier only on liquidation).
• Voting: each Series D preferred outstanding is entitled to 100 votes per share at stockholder meetings.
• Source/authority: issued pursuant to the Board of Directors Agreement dated February 3, 2025 (compensation for board services).
• Shares owned after the transaction: not specified in the provided filing.

Context: This was a compensation grant of convertible preferred stock to a director, not a cash purchase or sale. The filing shows $0 as the transaction value because the shares were issued as compensation; any eventual economic value will depend on future conversion and the market price of the common stock, within the stated ownership and timing limits.